Literature DB >> 10704427

Cyclin D1 in parathyroid disease.

S M Mallya1, A Arnold.   

Abstract

Primary hyperparathyroidism (HPT), most commonly due to parathyroid adenoma, is a disorder characterized by excessive secretion of PTH. So far, abnormalities in two genes, cyclin D1 and MEN1, have been implicated in the development of parathyroid adenomas. Cyclin D1, now an established Oncogene involved in numerous human cancers, was first identified and recognized as an Oncogene in the study of parathyroid tumors. A subset of parathyroid adenomas contains a clonal rearrangement that places the PTH gene's regulatory sequences in proximity to the cyclin D1 Oncogene causing its overexpression, and 20-40% of parathyroid adenomas overexpress the cyclin D1 protein. Transgenic animal models have further confirmed the role of cyclin D1 as a driver of abnormal parathyroid cell proliferation. Future studies on the mechanism of cyclin D1's oncogenicity and its interactions with other parathyroid growth regulators will further our understanding of parathyroid cell biology and may prove useful clinically.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10704427     DOI: 10.2741/mallya

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  8 in total

1.  Cyclin D1 overexpression increases susceptibility to 4-nitroquinoline-1-oxide-induced dysplasia and neoplasia in murine squamous oral epithelium.

Authors:  Jonathan F Wilkey; Glenn Buchberger; Kirsten Saucier; Salony M Patel; Ellen Eisenberg; Hiroshi Nakagawa; Carmen Z Michaylira; Anil K Rustgi; Sanjay M Mallya
Journal:  Mol Carcinog       Date:  2009-09       Impact factor: 4.784

2.  Identification of differentially expressed microRNA in parathyroid tumors.

Authors:  Reza Rahbari; Alisha K Holloway; Mei He; Elham Khanafshar; Orlo H Clark; Electron Kebebew
Journal:  Ann Surg Oncol       Date:  2010-11-18       Impact factor: 5.344

Review 3.  Molecular genetics in primary hyperparathyroidism: the role of genetic tests in differential diagnosis, disease prevention strategy, and therapeutic planning. A 2017 update.

Authors:  Francesca Marini; Luisella Cianferotti; Francesca Giusti; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2017-05-30

4.  Cyclin D1 G870A polymorphism: Association with uterine leiomyoma risk and in silico analysis.

Authors:  Saeedeh Salimi; Mahnaz Shahrakipour; Azam Hajizadeh; Mojgan Mokhtari; Mahdieh Mousavi; Batool Teimoori; Minoo Yaghmaei
Journal:  Biomed Rep       Date:  2016-12-21

5.  A systematic investigation based on microRNA-mediated gene regulatory network reveals that dysregulation of microRNA-19a/Cyclin D1 axis confers an oncogenic potential and a worse prognosis in human hepatocellular carcinoma.

Authors:  Yanqiong Zhang; Xiaodong Guo; Zhiwei Li; Boan Li; Zhiyan Li; Ruisheng Li; Qiuyan Guo; Lu Xiong; Lingxiang Yu; Jingmin Zhao; Na Lin
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

6.  Regulator of G protein signaling 5 is highly expressed in parathyroid tumors and inhibits signaling by the calcium-sensing receptor.

Authors:  James Koh; Moahad Dar; Brian R Untch; Darshana Dixit; Yuhong Shi; Zhao Yang; Mohamed Abdelgadir Adam; Holly Dressman; Xiaojuan Wang; Diane Gesty-Palmer; Jeffrey R Marks; Robert Spurney; Kirk M Druey; John A Olson
Journal:  Mol Endocrinol       Date:  2011-03-10

7.  Molecular alterations in sporadic primary hyperparathyroidism.

Authors:  Maria Inês Alvelos; Maria Mendes; Paula Soares
Journal:  Genet Res Int       Date:  2011-09-08

Review 8.  Diagnosis, management, histology and genetics of sporadic primary hyperparathyroidism: old knowledge with new tricks.

Authors:  Maria Mizamtsidi; Constantinos Nastos; George Mastorakos; Roberto Dina; Ioannis Vassiliou; Maria Gazouli; Fausto Palazzo
Journal:  Endocr Connect       Date:  2018-01-12       Impact factor: 3.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.